Supporting grooms in equestrian sports
Find out how one organization can change the lives of those who dedicate their careers to horse care.
Search
Building Lasting Partnerships for a Better Future
Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.
Singapore
Singapore Boehringer Ingelheim Singapore in an overview: Learn more about locations.
Facing Pulmonary Fibrosis
Steve Jones talks about his experience facing his pulmonary fibrosis diagnosis.
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Boehringer Ingelheim Innovation Prize
Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
EMPRISE-Study
EMPRISE-Study
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
Production Insights
Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals
Animal Welfare through environmental sustainability
Producing honey and contributing to environmental sustainability during your work hours.
Improving Access to Healthcare
According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
Five things we look for in our employees
Find out what skills, qualifications and experience we look for in our Boehringer Ingelheim employees and learn more about our People Promise.
Spesolimab meets key endpoint for GPP flare prevention
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
Real stories, real impact: fighting rabies
The danger of rabies is often overlooked. The need for action, unseen. Learn how we can eliminate rabies through leveraging education and dog vaccinations.
Spesolimab (BI 655130): IL36R antibody
Spesolimab (BI 655130): IL36R antibody
Spesolimab (BI 655130): IL36R antibody
Spesolimab (BI 655130): IL36R antibody
Spesolimab (BI 655130): IL36R antibody | PG
Spesolimab (BI 655130): IL36R antibody | PG
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Innovation Prize Winners
Find out more about the winners of our Innovation Prize in Boston, New York and San Diego in the USA; Tokyo Japan and Vienna, Austria
New positive data in Phase III type 2 diabetes trial
DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes
Rabies wildlife 5 things to know
Rabies in wildlife - 5 things to know to protect yourself and your pet
A Unique Bond: there’s nothing like it
It's not easy to live with systemic sclerosis, but the remarkable relationship Anna has built with Csenge has helped her realise her capabilities.
EMPERIAL-heart-failure-toplineresults
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
New partnership to develop schizophrenia treatments
Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments